20190522-TG-AGM-2019-EN
Category: 2019
Financial visibility extended to Q4 2020, including $10 million revenue from collaboration with AstraZeneca to be received in Q2 2019
20190513-Resultats-Q1-2019-EN-
Transgene receives FDA IND Clearance for Lead myvac® Individualized Immunotherapy, TG4050, to Commence Clinical Development in Ovarian Cancer
20190513 PR IND TG4050 EN
Transgene Announces Upcoming Investor Meetings
20190509 PR financial meetings Q2 19
Availability of Preparatory Documents for the Combined General Meeting of May 22, 2019
20190509MISE A DISPO AG – US
Transgene and AstraZeneca enter into a collaboration and exclusive license option agreement for innovative Invir.IO(TM) based armed oncolytic immunotherapies
20190502 – TG-AZ agreement – ENG
The efficacy and safety of Tipapkinogen Sovacivec (TG4001) therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up
Diane M. Harper, et al. Gynecologic Oncology, April 2019 – Download the article The publication has been featured in The Lancet Oncology and Medpage Today Publication
The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism
Johann Foloppe, et al. Molecular Therapy Oncolytics, March 2019 – Download the article Publication
Transgene and BioInvent Extend their Collaboration to Develop Multifunctional Oncolytic Viruses for the Treatment of Solid Tumors
20190326 PR BioInvent extension CDR US
Transgene: A positive 2018, moving ahead with a strong portfolio
20180320 FY RESULTS EN
